This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.


Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


Autocrine signaling

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 9: Line 9:
''Interleukin 1''
''Interleukin 1''
-
 
+
*[[Interleukins]]
An example of an autocrine agent is the cytokine interleukin-1 in monocytes (see [[Interleukin]]). When interleukin-1 is produced in response to external stimuli, it can bind to cell-surface receptors on the same cell that produced it (see [[Interleukin receptors]]).
An example of an autocrine agent is the cytokine interleukin-1 in monocytes (see [[Interleukin]]). When interleukin-1 is produced in response to external stimuli, it can bind to cell-surface receptors on the same cell that produced it (see [[Interleukin receptors]]).
'''Interleukin 6'''
'''Interleukin 6'''
-
*[[Interleukins]]
+
 
 +
 
Several studies have outlined the importance of autocrine IL-6 signaling in lung and breast cancers. For example, one group found a positive correlation between persistently activated tyrosine-phosphorylated [[Stepler sandbox STAT3|STAT3]] (pSTAT3), found in 50% of lung adenocarcinomas, and IL-6. Further investigation revealed that mutant [[EGFR]] could activate the oncogenic STAT3 pathway via upregulated IL-6 autocrine signaling. Similarly, HER2 overexpression occurs in approximately a quarter of breast cancers and correlates with poor prognosis. Recent research revealed that IL-6 secretion induced by [[HER2]] overexpression activated STAT3 and altered gene expression, resulting in an autocrine loop of IL-6/STAT3 expression. Both mouse and human in vivo models of HER2-overexpressing breast cancers relied critically on this HER2–IL-6–STAT3 signaling pathway.
Several studies have outlined the importance of autocrine IL-6 signaling in lung and breast cancers. For example, one group found a positive correlation between persistently activated tyrosine-phosphorylated [[Stepler sandbox STAT3|STAT3]] (pSTAT3), found in 50% of lung adenocarcinomas, and IL-6. Further investigation revealed that mutant [[EGFR]] could activate the oncogenic STAT3 pathway via upregulated IL-6 autocrine signaling. Similarly, HER2 overexpression occurs in approximately a quarter of breast cancers and correlates with poor prognosis. Recent research revealed that IL-6 secretion induced by [[HER2]] overexpression activated STAT3 and altered gene expression, resulting in an autocrine loop of IL-6/STAT3 expression. Both mouse and human in vivo models of HER2-overexpressing breast cancers relied critically on this HER2–IL-6–STAT3 signaling pathway.
-
+
 
 +
''Interleukin 7''
 +
 
 +
A study demonstrates how the autocrine production of the IL-7 cytokine mediated by T-cell acute lymphoblastic leukemia (T-ALL) can be involved in the oncogenic development of T-ALL and offer novel insights into T-ALL spreading.
</StructureSection>
</StructureSection>
== References ==
== References ==
<references/>
<references/>

Revision as of 06:47, 8 May 2022

Structure of Human VEGF-A dimer, 1vpf

Drag the structure with the mouse to rotate

References

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky

Personal tools